Data Under Review
Some valuation figures for this stock are being recalibrated. Hidden fields will return after data review.
Reported as ticker: SPARC· We're continuously improving data quality. Contact support if this persists.
SUN PHARMA ADV.RES.CO.LTD
SPARC · General/Diversified · NSE
₹138
Current Market Price
Fair Value (DCF)
₹0
Margin of Safety
-100.0%
Updated 20h ago
YieldIQ Score
15/100
Piotroski F-Score
4/9
Economic Moat
None
Confidence
0%
ROE
—
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹4,482 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
—
Leverage vs earnings
Interest Coverage
-39.1×
EBIT covers interest
Current Ratio
0.07×
Short-term liquidity
Asset Turnover
0.21×
Revenue per ₹ of assets
Revenue CAGR (3Y)
-19.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹138.1
Bear case
₹0
MoS -Infinity%
Base case
₹0
MoS -Infinity%
Bull case
₹0
MoS -Infinity%
Ratio Trends
SPARC · last 9 annual periods
ROE
157.9%
ROCE
-667.9%
Operating Margin
—
Debt / Equity
0.37×
PE
—
EV / EBITDA
—
Historical Financials
SPARC · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹253 Cr | ₹137 Cr | ₹239 Cr | ₹75.5 Cr | ₹71.8 Cr | -27.0% |
| EBITDA | — | ₹-180 Cr | ₹-203 Cr | ₹-373 Cr | ₹-322 Cr | — |
| EBIT | ₹-140 Cr | ₹-190 Cr | ₹-81.8 Cr | ₹-105 Cr | — | — |
| PAT | ₹-151 Cr | ₹-203 Cr | ₹-82.0 Cr | ₹-106 Cr | ₹-343 Cr | — |
| EPS (diluted) | ₹-5.77 | ₹7.73 | ₹-2.55 | ₹-3.26 | — | — |
| CFO | ₹-152 Cr | ₹-208 Cr | ₹-69.1 Cr | ₹-429 Cr | ₹-360 Cr | — |
| CapEx | — | — | — | — | ₹-10.3 Cr | — |
| FCF | — | — | — | — | ₹-371 Cr | — |
| Total Assets | — | ₹280 Cr | ₹830 Cr | ₹515 Cr | ₹336 Cr | +4.6% |
| Total Debt | — | — | ₹0.1 Cr | ₹47.0 Cr | ₹265 Cr | +753.3% |
| Shareholders' Equity | — | — | ₹513 Cr | ₹126 Cr | ₹-217 Cr | — |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SPARC vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| INNOVACAP INNOVACAP | — | — | Pending | 13.4% | — |
| GUJTHEM GUJTHEM | — | — | Pending | 19.6% | — |
| AARTIDRUGS AARTIDRUGS | — | — | Pending | 12.3% | — |
| RPGLIFE RPGLIFE | — | — | Pending | 34.5% | — |
| GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SPARC in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SPARC →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SPARC →
Compare
Head-to-head with peers
Compare SPARC side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SPARCNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.